Experimental immune cells take on tough tumors

NCT ID NCT06562647

Recruiting now Disease control Sponsor: Cell Origin Biotech (Hangzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early trial tests a new treatment called SY001, which uses a patient's own immune cells (macrophages) engineered to attack cancer cells that have a protein called mesothelin. The study includes just 2 people with advanced ovarian or pancreatic cancer who have not responded to prior treatments. The main goal is to check safety and find the right dose, not yet to cure the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SY001 (CAR-macrophage cells targeting mesothelin)
What this could lead to: If successful, this could point toward a new cell therapy for hard-to-treat solid tumors like advanced ovarian and pancreatic cancers.
What could go wrong: This is a very early, tiny trial (only 2 people) focused on safety and dosing. It is too small to prove effectiveness, and cell therapies can have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma Neoplasms, Second Primary ovarian cancer secondary malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER TREATMENT RELATED CANCER

Contacts and locations

Locations

Linyi Cancer Hospital
NOT_YET_RECRUITING

Linyi, China
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.